maraviroc (Selzentry)

From Aaushi
Jump to navigation Jump to search

Indications

  • adjunctive treatment of multi-drug resistant HIV
  • susceptibility testing required prior to initiating treatment

Contraindications

Dosage

start 300 mg PO BID

Pharmacokinetics

Adverse effects

Drug interactions

Laboratory

Mechanism of action

  • inhibits entry of HIV1 into cells when HIV1 uses CCR5 to gain entry into cells (50-60% of HIV1 strains)

More general terms

References

  1. Prescriber's Letter 14(9): 2007 New Drug: Selzentry (Maraviroc) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=230904&pb=PRL (subscription needed) http://www.prescribersletter.com
  2. Gulick RM et al Maraviroc for Previously Treated Patients with R5 HIV-1 Infection NEJM 359:1429-1441 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18832244
  3. 3.0 3.1 Aberg JA et al Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19640227
  4. 4.0 4.1 Zuger A Use of Antiretroviral Drugs in Pregnancy. Physician's First Watch, April 22, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
    Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2014. AIDSinfo. Clinical Guidelines Portal. March 28, 2014. http://aidsinfo.nih.gov/Guidelines/HTML/3/perinatal-guidelines/0 (corresponding NGC guideline withdrawn March 2016)
  5. Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015

Database